Compare BKE & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKE | WVE |
|---|---|---|
| Founded | 1948 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 1996 | 2015 |
| Metric | BKE | WVE |
|---|---|---|
| Price | $50.75 | $13.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | ★ $55.00 | $30.73 |
| AVG Volume (30 Days) | 308.0K | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 8.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $1,217,689,000.00 | $3,704,000.00 |
| Revenue This Year | $7.42 | $16.76 |
| Revenue Next Year | $2.75 | $149.85 |
| P/E Ratio | $20.58 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $33.12 | $5.28 |
| 52 Week High | $61.69 | $21.73 |
| Indicator | BKE | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 45.40 |
| Support Level | $47.15 | $12.53 |
| Resistance Level | $56.56 | $14.56 |
| Average True Range (ATR) | 1.48 | 0.78 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 15.79 | 20.34 |
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.